Cortical hyperostosis following long-term administration of prostaglandin E1 in infants with cyanotic congenital heart disease

Ueda, Ken; Saito, Akihiro; Nakano, Hiroyuki; Aoshima, M; Yokota, Michio; Muraoka, Ryusuke; Iwaya, Tsutomu

doi:10.1016/s0022-3476(80)80282-4

Cited by 267 publications

(77 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, we must take care before coming to a firm conclusion. PGs in vivo can, unlike in vitro, cause bone formation (Ueda et al, 1980), and cyclo-oxygenase inhibitors may increase the metabolism of PG precursors into lipoxygenase products (Higgs et al, 1980), some of which potently resorb bone in vitro (Meghji et al, 1988). Furthermore, skeletal scans are not always reliable indicators of bone metastases (Coombes et al, 1983), and this might explain why a few of our scanpositive patients were negative on subsequent retesting.…”

Section: Resultsmentioning

confidence: 91%

Breast cancer, prostaglandins and patient survival

Bennett

Stamford²,

Berstock³

et al. 1989

Br J Cancer

View full text Add to dashboard Cite

Summary Prostaglandins may have both undesirable and desirable effects in malignant disease. Their possible roles in breast cancer were studied by examining the relationships between different variables and the amounts of prostaglandin-like material (PG-LM) extracted from 141 breast carcinomas. Univariate analysis indicates a direct correlation with patient age and menopausal status, with a greater yield from cancers of post-compared with pre-menopausal women. Tumours up to 2cm diameter yielded more PG-LM than those measuring >2-5cm. Although there was also a direct correlation with bone metastasis near to the time of surgery, this was because no positive bone scans occurred in patients whose tumours yielded little total PG-LM (<16ng PGE2 equivalents per g tissue). Since tumour PG-LM did not predict later spread to bone, and yields of > 16 ng g -' were similar in the positive and negative bone scan groups, tumour PG-LM appears to be unimportant for skeletal metastasis. There was no obvious relationship of tumour PG-LM to the grade of malignancy, tumour type, amounts of fibrous tissue (and therefore malignant cells), invasion of blood vessels and lymphatics or presence of plasma cells. Multivariate analysis indicates that disease-free survival is longest with an intermediate production of tumour total PG-LM. Of the 82 patients now dead, the cause was attributed to metastatic disease in 69 cases. No relationship of PG-LM to the length of survival was seen with univariate or multivariate analysis. However, when just the post-menopausal patients who died within the first 3 postoperative years were analysed, there was a highly significant inverse correlation between the tumour total PG-LM and the time to death. The reason(s) for these different findings on overall survival compared with just the patients who died are not understood, but the results may indicate that one or more other variables must co-exist with a high tumour PG-LM to hasten death.Many tumours can produce more prostaglandins (PGs) than the normal tissues in which they arise (Bennett, 1979(Bennett, , 1982(Bennett, , 1988. Similarly, more prostglandin-like material (PG-LM), assayed on rat gastric fundus which is most sensitive to PGE2, was extracted from homogenates of human mammary carcinomas than from benign tumours or macroscopically normal breast tissue (Bennet et al., 1977). Various PGs and related substances extracted from breast carcinomas were identified by Stamford et al. (1983) using gas chromatography-mass spectrometry; the products were arachidonate, 12-hydroxy-eicosatetraenoate (12-HETE), thromboxane B2, 15-keto-l 3,14-dihydro-TXB2, 6-keto-PGFJ,, 6,15-diketo-PGF1,,, 615-diketo-1 3,14-dihydro-PGF1,,, PGD2, PGE2 and PGF21,. Quantitative gas chromatography-mass spectrometry showed substantial amounts of 6-keto-PGF, . and some PGD2, PGE2 and PGF20,, with much higher yields of arachidonate (Stamford et al., 1986). It might be expected that these potent substances contribute to breast cancer, but the problem is complex because PGs have numerou...

show abstract

Section: Resultsmentioning

confidence: 91%

Breast cancer, prostaglandins and patient survival

Bennett

Stamford²,

Berstock³

et al. 1989

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Furthermore, PGE 2 influences the differentiation of chondrocytes as previously shown for the chondrocyte cell line RCJ3.1C5.18 (Lowe et al 1996) and for rat growth plate chondrocytes (Schwartz et al 1998, O'Keefe et al, 1992. In addition to such findings in cell culture, the physiological role of prostaglandins was clarified by its stimulating effect on bone formation and increase in bone mass after systemic administration of PGE 2 to infants (Ueda et al, 1980) and animals (Suponitzki & Weinreb, 1998). Interestingly, also local administration of PGE 2 resulted in osteogenesis in situ (Yang et al, 1993, Marks & Miller, 1988 , 1999).…”

Section: Prostaglandin Ementioning

confidence: 73%

Growth Factors and Signalling Molecules for Cartilage Tissue Engineering – from Embryology to Innovative Release Strategies for Guided Tissue Engineering

Brochhausen¹,

Zehbe²,

Watzer³

et al. 2010

Tissue Engineering

View full text Add to dashboard Cite

“…Upon reviewing the literature, we found that PGE2 has a stimulatory effect in high doses on the division of prechondroblasts (Falconer et al 1980) and on the formation of fracture callus (Juhn et al 1989). Further, PGE2 and PGEl increase endosteal bone growth in infants and bone formation in dogs after rib fractures (Ueda et al 1980, Ueno et al 1985, Shih and Norrdin 1986, High 1987, Norrdin and Shih 1988. PGE2 might therefore be important in the initiation of bone healing.…”

Section: Discussionmentioning

confidence: 98%

Release of prostaglandins from bone and muscle after femoral osteotomy in rats

Wittenberg

1991

Acta Orthopaedica Scandinavica

View full text Add to dashboard Cite

Cortical hyperostosis following long-term administration of prostaglandin E1 in infants with cyanotic congenital heart disease

Cited by 267 publications

References 7 publications

Breast cancer, prostaglandins and patient survival

Breast cancer, prostaglandins and patient survival

Growth Factors and Signalling Molecules for Cartilage Tissue Engineering – from Embryology to Innovative Release Strategies for Guided Tissue Engineering

Release of prostaglandins from bone and muscle after femoral osteotomy in rats

Contact Info

Product

Resources

About